Chi-Med and Merck KGaA Start Collaboration to Discover Novel Small Molecule Anti-Cancer Drugs
Mr. Christian Hogg, CEO of Chi-Med, said: "Over the last four years, we have established a solid R&D organization that has brought two candidates into US phase II clinical studies in the oncology and auto-immune areas. We are delighted to partner with Merck to broaden our research activities in the oncology area. Merck has a good record of achievement in the development and commercialization of oncology products such as Erbitux. In addition, we believe this collaboration further validates Chi-Med's drug discovery capability."
Chi-Med sees Traditional Chinese Medicine as a major, under-exploited reservoir for the development of novel drugs for the global pharmaceutical market and for developing new products for the global health and beauty consumer markets.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.